158 related articles for article (PubMed ID: 20072881)
1. Mannosylated liposomes for targeted vaccines delivery.
Vyas SP; Goyal AK; Khatri K
Methods Mol Biol; 2010; 605():177-88. PubMed ID: 20072881
[TBL] [Abstract][Full Text] [Related]
2. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.
Jain S; Singh P; Mishra V; Vyas SP
Immunol Lett; 2005 Oct; 101(1):41-9. PubMed ID: 15869802
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice.
Hattori Y; Kawakami S; Suzuki S; Yamashita F; Hashida M
Biochem Biophys Res Commun; 2004 May; 317(4):992-9. PubMed ID: 15094367
[TBL] [Abstract][Full Text] [Related]
4. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response.
Brgles M; Habjanec L; Halassy B; Tomasić J
Vaccine; 2009 Sep; 27(40):5435-42. PubMed ID: 19632317
[TBL] [Abstract][Full Text] [Related]
5. Mannosylated liposomes for bio-film targeting.
Vyas SP; Sihorkar V; Jain S
Int J Pharm; 2007 Feb; 330(1-2):6-13. PubMed ID: 16997519
[TBL] [Abstract][Full Text] [Related]
6. Development of novel fusogenic vesosomes for transcutaneous immunization.
Mishra V; Mahor S; Rawat A; Dubey P; Gupta PN; Singh P; Vyas SP
Vaccine; 2006 Jul; 24(27-28):5559-70. PubMed ID: 16730102
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
8. Mannosylated niosomes as carrier adjuvant system for topical immunization.
Jain S; Vyas SP
J Pharm Pharmacol; 2005 Sep; 57(9):1177-84. PubMed ID: 16105238
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route.
Tiwari B; Agarwal A; Kharya AK; Lariya N; Saraogi G; Agrawal H; Agrawal GP
J Liposome Res; 2011 Sep; 21(3):181-93. PubMed ID: 20626315
[TBL] [Abstract][Full Text] [Related]
10. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
11. Gel core liposomes: an advanced carrier for improved vaccine delivery.
Tiwari S; Goyal AK; Khatri K; Mishra N; Vyas SP
J Microencapsul; 2009 Feb; 26(1):75-82. PubMed ID: 18608797
[TBL] [Abstract][Full Text] [Related]
12. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo.
Sheng KC; Kalkanidis M; Pouniotis DS; Esparon S; Tang CK; Apostolopoulos V; Pietersz GA
Eur J Immunol; 2008 Feb; 38(2):424-36. PubMed ID: 18200633
[TBL] [Abstract][Full Text] [Related]
13. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
14. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes.
Korsholm KS; Agger EM; Foged C; Christensen D; Dietrich J; Andersen CS; Geisler C; Andersen P
Immunology; 2007 Jun; 121(2):216-26. PubMed ID: 17302734
[TBL] [Abstract][Full Text] [Related]
15. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration.
Hattori Y; Kawakami S; Lu Y; Nakamura K; Yamashita F; Hashida M
J Gene Med; 2006 Jul; 8(7):824-34. PubMed ID: 16625665
[TBL] [Abstract][Full Text] [Related]
16. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response.
Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
J Control Release; 2010 Jul; 145(2):102-8. PubMed ID: 20381556
[TBL] [Abstract][Full Text] [Related]
17. Surface modified liposomes for nasal delivery of DNA vaccine.
Khatri K; Goyal AK; Gupta PN; Mishra N; Mehta A; Vyas SP
Vaccine; 2008 Apr; 26(18):2225-33. PubMed ID: 18396362
[TBL] [Abstract][Full Text] [Related]
18. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes.
Espuelas S; Thumann C; Heurtault B; Schuber F; Frisch B
Bioconjug Chem; 2008 Dec; 19(12):2385-93. PubMed ID: 19053315
[TBL] [Abstract][Full Text] [Related]
19. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition.
Foged C; Arigita C; Sundblad A; Jiskoot W; Storm G; Frokjaer S
Vaccine; 2004 May; 22(15-16):1903-13. PubMed ID: 15121302
[TBL] [Abstract][Full Text] [Related]
20. Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cells.
White KL; Rades T; Furneaux RH; Tyler PC; Hook S
J Pharm Pharmacol; 2006 Jun; 58(6):729-37. PubMed ID: 16734974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
